Drug Trial Radar · NCT07180160
Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer
Last checked: Nov 19, 2026Latest source record: Nov 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
123
Planned (sponsor's estimate)
Start
Sep 25, 2025
Primary completion
Sep 2027
Study completion Mar 2028
Sponsor
- Lead sponsor
- Wenjin YinAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, randomised, controlled, multicentre study to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab (QL1706) in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer.
Conditions
- Advanced Breast Cancer
Interventions
QL1706Drug
QL1706 is a single bifunctional MabPair product consisting of two engineered monoclonal antibodies (anti-PD-1 and anti-CTLA-4).
CDK4/6 inhibitorDrug
palbociclib OR ribociclib OR abemaciclib OR dalpiciclib
FulvestrantDrug
SERD
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS)Time frame: From the date of starting study treatment to the date of first documentation of disease progression or death from any cause (up to approximately 1 year)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Renji Hospital, School of Medicine, Shanghai Jiaotong University
Shanghai, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.